This is a working overview of bremelanotide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-24 and is reviewed periodically as new material appears.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular weight | Approximately 1025 Da | Calculated from the peptide sequence |
| Appearance | White to off-white powder | Common for lyophilized peptide preparations |
| Solubility | Soluble in water | Also soluble in polar organic solvents |
| Storage temperature | -20 °C or below | Used for long-term retention |
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
For example, tendon has primarily parallel fibers, whereas skin consists of a net of wavy fibers, resulting in a much higher strength and lower ductility in tendon compared to skin. The mechanical properties of collagen at multiple hierarchical levels are given.
== Characteristics == Collagen is one of the long, fibrous structural proteins whose functions are quite different from those of globular proteins, such as enzymes. Tough bundles of collagen called "collagen fibers" are a major component of the extracellular matrix that supports most tissues and gives cells structure from the outside, but collagen is also found inside certain cells. Collagen has great tensile strength and is the main component of fascia, cartilage, ligaments, tendons, bone, and skin. Along with elastin and soft keratin, it is responsible for skin strength and elasticity, and its degradation leads to wrinkles that accompany aging. In the skin, collagen and elastin have complementary roles within the extracellular matrix. Collagen provides tensile strength and structural support, whereas elastin is a major component of elastic fibers that enables the skin to stretch and return toward its original shape. With intrinsic aging and chronic ultraviolet exposure, both collagen and elastic fiber networks undergo structural and quantitative changes, contributing to reduced skin elasticity, wrinkles, and laxity. Studies of dermal tissue have identified changes in the density and organization of both collagen and elastin as characteristic features of intrinsic aging and photoaging. In the skin, collagen and elastin have complementary roles within the extracellular matrix: collagen provides tensile strength and structural support, whereas elastin is the principal component of elastic fibers that allows skin to stretch and recoil toward its original shape.
=== Australia === An Australian edition was briefly published in early 2004, for less than six months. The Australian edition consisted mostly of content from the UK edition, along with news on the local games industry.
Sources: en.wikipedia.org
== Composition == Petroleum consists of a variety of liquid, gaseous, and solid components. Lighter hydrocarbons are the gases methane, ethane, propane and butane. Otherwise the bulk of the liquid and solids are largely heavier organic compounds, often hydrocarbons (C and H only). The proportion of light hydrocarbons in a petroleum mixture varies among oil fields. An oil well produces predominantly crude oil. Because the pressure is lower at the surface than underground, some of the gas will come out of solution and be recovered (or burned) as associated gas or solution gas. A gas well produces predominantly natural gas. However, because the underground temperature is higher than at the surface, the gas may contain heavier hydrocarbons such as pentane, hexane, and heptane ("natural-gas condensate", often shortened to condensate.) Condensate resembles gasoline in appearance and is similar in composition to some volatile light crude oils. The hydrocarbons in crude oil are mostly alkanes, cycloalkanes and various aromatic hydrocarbons, while the other organic compounds contain nitrogen, oxygen, and sulfur, and traces of metals such as iron, nickel, copper and vanadium. Many oil reservoirs contain live bacteria. The molecular composition of crude oil varies widely from formation to formation, but the proportion of chemical elements varies over fairly narrow limits as follows:
"What we know about the US-Israeli attack on Iran and Tehran's retaliation". CNN. 28 February 2026. Retrieved 28 February 2026. U.S. and Israeli Strikes on Iran, C-SPAN Tracking of traffic in the Strait of Hormuz
=== 238Pu === Plutonium-238 has a half-life of 87.7 years, reasonable power density of 0.57 watts per gram, and exceptionally low gamma and neutron radiation levels. 238Pu has the lowest shielding requirements. Only three candidate isotopes meet the last criterion (not all are listed above) and need less than 25 mm of lead shielding to block the radiation. 238Pu (the best of these three) needs less than 2.5 mm, and in many cases, no shielding is needed in a 238Pu RTG, as the casing itself is adequate. 238Pu has become the most widely used fuel for RTGs, in the form of plutonium(IV) oxide (PuO2). However, plutonium(IV) oxide containing a natural abundance of oxygen emits neutrons at the rate of roughly 2.3×104 n/sec/g of 238Pu. This emission rate is relatively high compared to the neutron emission rate of plutonium-238 metal. The metal containing no light element impurities emits roughly 2.8×103 n/sec/g of 238Pu. These neutrons are produced by the spontaneous fission of 238Pu. The difference in the emission rates of the metal and the oxide is due mainly to the alpha, neutron reaction with the oxygen-18 and oxygen-17 in the oxide. The normal amount of oxygen-18 present in the natural form is 0.204% while that of oxygen-17 is 0.037%. The reduction of the oxygen-17 and oxygen-18 present in the plutonium dioxide will result in a much lower neutron emission rate for the oxide; this can be accomplished by a gas phase 16O2 exchange method.
Sources: en.wikipedia.org
=== Ecology === Under natural conditions Brucella spp, including B. canis are obligate parasites and do not grow outside the host except in laboratory cultures. However, at specific temperatures and moisture levels Brucella can persist in soil and surface water up to 80 days. The bacterium can also survive for months in frozen conditions. B. canis is mainly found in dogs, but can also affect other wild canine species such as wolves, foxes, and coyotes. The bacterium persists in these hosts, being an adaptive pathogen towards canines. The environment these hosts reside in further contribute to the canine specificity. Dog kennels are a favored environment for the bacterium to spread due to transmission through urine and reproductive fluids. Movement of infected animals through pet trade or shelter transport also plays a critical role in the broader distribution of the bacterium. In wildlife, B. canis is also circulated through hunting and scavenging. Zoonotic transmission to humans is rare but possible, particularly for people in close contact with infected reproductive tissues. Certain occupations are at higher risk of exposure to B. canis. These persons include veterinarians, kennel workers, dog breeders, and laboratory personnel.
==== Knight Commander of the Order of the British Empire (KBE) ==== Military Division Vice Admiral Michael Antony Claes Moore, . Civil Division The Right Honourable Baron Thomas Alexander Fermor Hesketh. For political service.
== Side effects == One of the most common side effects of spironolactone is frequent urination. Other general side effects include dehydration, hyponatremia (low sodium levels), mild hypotension, ataxia (muscle incoordination), drowsiness, dizziness, dry skin, and rashes. Because of its antiandrogenic activity, spironolactone can cause breast tenderness, gynecomastia (breast development), feminization in general, and demasculinization, as well as sexual dysfunction including loss of libido and erectile dysfunction, although these side effects are usually confined to high doses. At very high doses (400 mg/day), spironolactone has also been associated with testicular atrophy and reversibly reduced fertility, including semen abnormalities, such as decreased sperm count and motility in men, but such doses of spironolactone are rarely used clinically. In women, spironolactone can cause menstrual irregularities, breast tenderness, and breast enlargement. Aside from these adverse effects, the side effects of spironolactone in women taking high doses are minimal, and it is well tolerated. A potential side effect of spironolactone is hyperkalemia (high potassium levels), which in severe cases, can be life-threatening. Hyperkalemia can present as a normal anion-gap metabolic acidosis. The addition of spironolactone to loop diuretics in people with heart failure reportedly was associated with a higher risk of hyperkalemia and acute kidney injury. Spironolactone may put people at a heightened risk for gastrointestinal issues such as nausea, vomiting, diarrhea, cramping, and gastritis.
=== 29 May === Russia launched its 15th air attack of the month and its second consecutive attack in Kyiv in the early morning hours. Damage was reported in the Podilskyi District, with a "one-storey private residence" being struck by falling debris. Debris was reported to have struck buildings in the Sviatoshyn and Holosiivskyi districts as well. The attack involved drones and cruise missiles. The Kyiv City Military Administration claimed to have shot down forty targets. Shortly afterwards during daytime, Russia launched its 16th attack on Kyiv for the month. The Ukrainian military said it had shot down 37 cruise missiles and 29 drones, along with 11 Iskander missiles. One person was injured. Ukrainian Air Force spokesman Yuriy Ihnat said that ballistic missiles, including either S-300 or S-400 missiles were used. An air base in Khmelnytskyi was also struck. Five aircraft were reported to have been disabled while the runway was reported to have been damaged. Russian artillery and helicopters also launched attacks on settlements in Sumy Oblast throughout the day. The Russian defence ministry later said it struck air bases during those attacks. In Donetsk Oblast, two civilians were killed by Russian shelling in Toretsk, while eight others were injured. Another person was killed by Russian shelling in Kozatske, Kherson Oblast. One person was killed and nine others injured by shelling in Synelnykove Raion in Dnipropetrovsk Oblast, while seven people were injured by shelling in Kupiansk Raion, in Kharkiv Oblast.
Sources: en.wikipedia.org
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.
PDE5 inhibitors act on peripheral vascular tissue to increase blood flow. Bremelanotide acts centrally on melanocortin receptors and is associated with dopaminergic pathways. The two approaches therefore target different parts of the arousal response.
It is a synthetic peptide analog rather than a hormone produced by the body. Alpha-melanocyte-stimulating hormone is the natural peptide it resembles. The two share structural features but are distinct molecules.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.